Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614103 · ClinicalTrials.gov registry record · Phase 2
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
A Phase 2 study of Metastatic Non Small Cell Lung Cancer, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT04614103 is a Phase 2 study of Metastatic Non Small Cell Lung Cancer that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 170 participants, below the 388-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04614103, a Phase 2 study of Metastatic Non Small Cell Lung Cancer, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Conditions Studied
Interventions
- BIOLOGICAL LN-145
Study Locations (20)
Florida
- University of Florida Health Cancer Center - Gainesville
- Sylvester Comprehensive Cancer Center - Miami
- AdventHealth Cancer Institute - Orlando
- H Lee Moffitt Cancer Center and Research Institute - Tampa
California
- City of Hope - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- University of Southern California - Los Angeles
Illinois
- Rush University Medical Center - Chicago
- University of Illinois Hospital & Health Sciences System - Chicago
- Advocate Aurora Health - Park Ridge
Kentucky
- University of Kentucky-Markey Cancer Center - Lexington
- University of Louisville - Louisville
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Health System - Detroit
Delaware
- Christiana Care Health System - Newark
Georgia
- Augusta University - Augusta
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2031-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614103
The ClinicalTrials.gov registry entry for NCT04614103 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 388-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (56% lower). The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which LN-145 is the first listed.
NCT04614103 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT04614103 about?
NCT04614103 is a clinical study titled "Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer". This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
What is the current status of trial NCT04614103?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2021-05-07. Estimated completion is 2031-12.
What conditions does trial NCT04614103 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT04614103?
The interventions under investigation include: LN-145 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04614103?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04614103 being conducted?
This trial has 20 study locations across California, Delaware, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
RECRUITING · Phase 2
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RECRUITING · Phase 2
-
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
-
Plasma-Adapted First-Line Pembro In NSCLC
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.